Clinical outcomes in patients with piperacillin/ tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection

头孢曲松 医学 哌拉西林/他唑巴坦 他唑巴坦 哌拉西林 内科学 抗生素 肺炎克雷伯菌 胃肠病学 外科 微生物学 抗生素耐药性 亚胺培南 生物 大肠杆菌 细菌 生物化学 遗传学 基因 铜绿假单胞菌
作者
Ahmad Mourad,Austin E. Smith,Jesse D. Troy,Thomas L Holland,Rebekah Wrenn,Nicholas Turner
出处
期刊:Journal of Antimicrobial Chemotherapy [Oxford University Press]
标识
DOI:10.1093/jac/dkae134
摘要

Abstract Background A small proportion of Escherichia coli and Klebsiella pneumoniae demonstrate in vitro non-susceptibility to piperacillin/tazobactam but retain susceptibility to ceftriaxone. Uncertainty remains regarding how best to treat these isolates. Objectives We sought to compare clinical outcomes between patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection receiving definitive therapy with ceftriaxone versus an alternative effective antibiotic. Methods We retrospectively identified patients with a positive blood culture for piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae between 1 January 2013 and 31 December 2022. Patients were divided into one of two definitive treatment groups: ceftriaxone or alternative effective antibiotic. Our primary outcome was a composite of 90 day all-cause mortality, hospital readmission, or recurrence of infection. We used Cox proportional hazards models to compare time with the composite outcome between groups. Results Sixty-two patients were included in our analysis. Overall, median age was 63 years (IQR 49.5–71.0), the most common source of infection was intra-abdominal (25/62; 40.3%) and the median total duration of therapy was 12.0 days (IQR 9.0–16.8). A total of 9/22 (40.9%) patients in the ceftriaxone treatment group and 18/40 (45.0%) patients in the alternative effective antibiotic group met the composite endpoint. In an adjusted time-to-event analysis, there was no difference in the composite endpoint between groups (HR 0.67, 95% CI 0.30–1.50). The adjusted Bayesian posterior probability that the HR was less than or equal to 1 (i.e. ceftriaxone is as good or better than alternative therapy) was 85%. Conclusions These findings suggest that ceftriaxone can be used to effectively treat bloodstream infections with E. coli or K. pneumoniae that are non-susceptible to piperacillin/tazobactam but susceptible to ceftriaxone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助nczpf2010采纳,获得10
2秒前
搜集达人应助杜兰特工队采纳,获得10
7秒前
热心市民小红花应助牛马采纳,获得10
9秒前
热心市民小红花应助牛马采纳,获得10
9秒前
9秒前
Ava应助WJM采纳,获得10
13秒前
科研通AI2S应助nczpf2010采纳,获得10
14秒前
酷酷飞烟发布了新的文献求助10
14秒前
Bressanone发布了新的文献求助10
16秒前
李健的小迷弟应助老吴采纳,获得10
16秒前
大气的雅山完成签到,获得积分10
18秒前
shaoshao86完成签到,获得积分10
24秒前
24秒前
华仔应助科研通管家采纳,获得10
24秒前
逆时针应助科研通管家采纳,获得10
24秒前
MchemG应助科研通管家采纳,获得10
24秒前
研友_VZG7GZ应助科研通管家采纳,获得10
24秒前
wang应助科研通管家采纳,获得10
24秒前
wang应助科研通管家采纳,获得10
24秒前
ding应助科研通管家采纳,获得10
24秒前
上官若男应助科研通管家采纳,获得10
25秒前
思源应助科研通管家采纳,获得10
25秒前
田様应助科研通管家采纳,获得10
25秒前
小北发布了新的文献求助10
25秒前
NexusExplorer应助Quinna采纳,获得10
27秒前
28秒前
28秒前
量子星尘发布了新的文献求助10
30秒前
WJM发布了新的文献求助10
34秒前
老吴发布了新的文献求助10
35秒前
36秒前
佳语妍说完成签到,获得积分10
37秒前
38秒前
39秒前
酷波er应助平淡的凝竹采纳,获得10
40秒前
42秒前
小星星发布了新的文献求助10
42秒前
田様应助c_123采纳,获得10
42秒前
45秒前
45秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073